Hints and tips:
Related Special Reports
...“Is the biosimilar market a failure with respect to these pharmacy benefit drugs like Humira?...
...Eli Lilly, the world’s largest drugmaker by market value, has struck a deal that will allow Amazon’s online pharmacy business to dispense medication, including its hugely popular weight loss injection pen...
...Adam Fein, president of Drug Channels Institute, said Amazon Pharmacy “continues to garner attention . . . beyond its actual impact on the pharmacy industry”....
...Ain Holdings, the largest prescription drugstore chain with more than 1,200 dispensing pharmacies in Japan, has become the latest target....
...Ecuador has reached a deal with the IMF worth about $4bn in financing over four years, as the South American country seeks to loosen its constrained finances amid a crackdown on drug traffickers....
...A weight-loss drug licensed by Boehringer Ingelheim from Danish biotech Zealand Pharma has had positive results in liver disease trials, while Novo Nordisk is looking at the effect of its weight-loss drug...
...The higher number of shortages has also led to the government reimbursing pharmacies for buying drugs above their standard cost more frequently....
...The reforms will encourage pharmacy benefit managers to limit use of the most expensive drugs. That will hit companies like AstraZeneca, maker of oral cancer drugs such as Tagrisso....
...But Eli Lilly declined to say how much of the product would be available in Britain, or which pharmacies will stock the product. Patients in Northern Ireland will not have access to the pen....
...Chief executive Lars Fruergaard Jørgensen told the Financial Times this month that it was assessing deals for biotech companies with mid-stage drugs....
...The problem is recurrent and widespread: in 2022 and 2023, national pharmacy bodies across 26 European countries all reported shortages, with the picture worsening last year....
...By these dubious criteria, it is impossible to deny that Potter Payper is the real deal....
...It follows a surge in the drug’s popularity and a lack of supplies, which has prompted patients to turn to illegal online pharmacies....
...Shares in CVS Health fell more than 8.1 per cent at the close on Thursday after a decision was made by the insurer to drop its Caremark unit as its main pharmacy benefit manager (PBM)....
...The insurer said the US drug purchasing system, which is dominated by PBMs — essentially drug middlemen — is “broken”, and that it expects to save $500mn in annual drug costs with its new model....
...Scientists have invented a potential drug candidate that successfully combats antibiotic-resistant “superbugs” in non-human tests, according to research....
...This deal is being forced on Japan by demographics, but the idea applies more widely....
...Roche and AstraZeneca have already struck deals to buy or license early stage weight-loss drugs....
...Jesse Mark, head of equity capital markets at Jefferies, said the most notable shift was an increase in “opportunistic” deals from companies whose fundraising was not linked to encouraging drug trial data...
...Medical supplies, from anaesthesia to everyday basic drugs, are scarce....
...In acquiring Fusion and Amolyt, the deal takes AstraZeneca’s M&A spending to $3.4bn in the past week....
...Roche and AstraZeneca have acquired or signed licensing deals with biotechs developing weight-loss treatments in the past year....
...Groups seeking to harness mind-altering substances including MDMA, psilocybin mushrooms and 5-MeO-DMT, a hallucinogen found in desert toad secretions, raised at least $163mn across five deals in January,...
...At the same time, attractive parts of drugstores’ business, such as specialist drugs like Humira for rheumatoid arthritis and high-cost therapies for oncology, are increasingly moving away from pharmacies...
International Edition